Return to the Clinical Trials Homepage

Who Qualifies?

Dogs with epilepsy that are receiving conventional anticonvulsants and having at least two seizures per month.  Upon enrollment, every dog will be evaluated by a neurologist and any medication adjustments will be made prior to starting the trial.

Purpose of the Study

The aim of this study is to assess the efficacy of a component of the Cannabis sativa plant, cannabidiol (CBD), in treating canine epilepsy. The CBD product is very low in the psychoactive component of cannabis, THC, making it safe for use in dogs. Each dog will be randomly assigned to either a control group or a treatment group, where they will receive the CBD oil or a placebo for 12 weeks. 

What is Required?

• An MRI of the brain and a spinal tap to rule out any other causes of seizures
• A daily seizure log and behavioral questionnaire filled out by a single owner
• Reassessment and bloodwork every 4 weeks

Benefits

All costs related to the study will be covered in full, including the examinations, MRI, spinal tap, bloodwork and the CBD oil.

To Enroll

Interested participants can learn more by contacting one of our research technicians by emailing CSUNeuroTrials@colostate.edu or Dr. Stephanie McGrath, or by calling (970) 305-0455​.

Informed Owner Consent Form